Travere Therapeutics Inc
Research Travere Therapeutics Inc (TVTX) on Bullrun: market cap USD 6.31B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTVTX
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 6.31B
- Financial periodQ2 2026
- RevenueUSD 169.58M
- Net income-USD 34.80M
- Free cash flowUSD 37.00M
- Gross margin94.6%
Valuation Snapshot
latest market cap is USD 6.31B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 490.73M | -USD 25.55M | -USD 20.37M | 97.9% | -0.29 | USD 93.04M | USD 328.73M | USD 114.83M |
| FY2024 | USD 233.18M | -USD 321.55M | -USD 338.69M | 96.7% | -4.08 | USD 58.54M | USD 401.58M | USD 59.08M |
| FY2023 | USD 145.24M | -USD 111.40M | -USD 280.69M | 92.1% | -1.5 | USD 58.18M | USD 404.78M | USD 200.81M |
| FY2022 | USD 109.46M | -USD 278.48M | -USD 186.48M | 96.0% | -4.37 | USD 61.69M | USD 408.17M | USD 42.85M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 6.31B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 3.47B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.52B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 675.56M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 1.35B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.94B | n/a | n/a | n/a |
About Travere Therapeutics Inc
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II);
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Travere Therapeutics Inc's market cap?
Travere Therapeutics Inc's market capitalization is USD 6.31B.
What does Travere Therapeutics Inc do?
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.